Charles River has extensive capabilities in fragment-based drug discovery, offering access to expertise in screening, structural biology, and computational and medicinal chemistry.
Our range of fragment libraries and orthogonal fragment screening technologies allows us to customize a fragment-based lead discovery solution to a wide array of target types.
Our fragment-based drug discovery (FBDD) platform provides access to:
|Orthogonal Screening Technologies||Technologies include thermal shift assay, surface plasmon resonance (SPR) using Biacore™ instrumentation, isothermal titration calorimetry (ITC), NMR, high-concentration biochemical assay and X-ray crystallography|
|Structural Biology||Experience in the development of structure routes to support FBDD; in-house X-ray facility and Crystal Bank of structures|
|1,500 member core library, 500 member kinase focused set and 500 member 19F labelled set, all designed for fragment screening and rapid FBDD optimization of hits|
|Computational Chemistry||Proprietary fragment hit expansion techniques and fragment shape-based analysis tools|
|Medicinal Chemistry||Expertise in structure-based drug discovery and fragment hit optimization|